Wir nutzen Cookies auf unserer Website. Einige von ihnen sind essenziell, während andere uns helfen, diese Website und Ihre Erfahrung zu verbessern.
Schützt vor Cross-Site-Request-Forgery Angriffen.
Retention period: Dieses Cookie bleibt nur für die aktuelle Browsersitzung bestehen.
Speichert die aktuelle PHP-Session.
Retention period: Dieses Cookie bleibt nur für die aktuelle Browsersitzung bestehen.
Inhalte von Drittanbietern, bspw. Aktienwidgets, werden standardmäßig blockiert. Wenn Cookies von Drittanbietern akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Einwilligung mehr.
Wir verwenden zur Aktien-Chart-Anzeige den Anbieter TradingView. Dieser setzt weitere Cookies zur Analyse seiner Dienste ein.
Sie können unseren Newsletter abonnieren, dazu nutzen wir die Dienste von EQS. Dieser Anbieter setzt bei der Registrierung selbst verschiedene Cookies zur Nutzungsanalyse seiner Dienste ein.
Seoul and Schönefeld, 25th October 2021 - HAEMATO PHARM GmbH ("HAEMATO"), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its own portfolio with a botulinum toxin product from the pharmaceutical company Huons Bio Pharma Co., Ltd. ("Huons BioPharma"), based in Seoul, Korea. For this purpose, Huons BioPharma and HAEMATO have …
HAEMATO continues to grow strongly: in the second quarter of 2021, preliminary consolidated revenue increased by around 41% to 77.6 million euros - after already growing by 22% in the first quarter of 2021. Preliminary half-year revenue for 2021 rose to 151.5 million euros, representing year-on-year growth of 31%. Preliminary EBIT rose to 4.8 …
HAEMATO AG (ISIN: DE000289VV1), has continued its growth course in the first months of 2021. Due to a strong core business, consolidated sales (IFRS) increased by 22% to EUR 73.9 million in the first quarter of 2021. The specialist in drugs for the treatment of chronic diseases and for individual therapies increased earnings disproportionately at …
Ad hoc of HAEMATO AG pursuant to Art. 17 MAR: The Supervisory Board of HAEMATO AG approved the Executive Board’s proposal for the appropriation of profits at today’s balance sheet meeting. The Executive Board and Supervisory Board will therefore propose a dividend of EUR 1.00 per dividend-bearing share at the Annual General Meeting to be […]
Corporate News of HAEMATO AG: According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million. In the 2020 financial year, HAEMATO AG, Schoenefeld (ISIN: DE000289VV1), achieved IFRS consolidated revenues of EUR […]
HAEMATO AG (ISIN: DE000A289VV1, WKN: A289VV) has successfully completed the capital increase which was announced on March 24, 2021. The capital increase was oversubscribed. The Company increased its share capital by € 475,391.00 to € 5,229,307.00 by issuing a total of 475,391 no-par value bearer shares against cash contributions, excluding …